ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 0121 • ACR Convergence 2021

    The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression

    Josefina Duran, Alvaro Verges, Ana Rocío Vázquez-Taboada, Matias Gonzalez and Lydia Gomez-Pérez, Pontificia Universidad Católica de Chile, Santiago, Chile

    Background/Purpose: Fibromyalgia (FM) and major depression frequently coexist. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce.…
  • Abstract Number: 0207 • ACR Convergence 2021

    Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital

    Carmen Álvarez-Reguera1, Jorge Javier Gaitán-Valdizán1, Raúl fernández-ramón1, Rosalia Demetrio-Pablo1, José Luis Martin-Varillas2, Lara Sánchez-Bilbao1, David Martinez-Lopez1, Iñigo Gonzalez-Mazon3, Miguel Ángel gonzalez-Gay4 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3H. U. Marques de Valdecilla, Santander, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Ocular involvement is a relatively frequent and potentially severe complication of sarcoidosis. Oral corticosteroids (OCS) are the first-line treatment. Conventional immunosuppressive agents (cIS) and…
  • Abstract Number: 0414 • ACR Convergence 2021

    Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study

    Roline Krol1, Caroline Schaap1, Paco Welsing1, Ruth Klaasen2, Hilde Remmelts2, Chris Hagen2, Franka van Reekum1, Marloes Heijstek1 and Julia Spierings1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Meander Medical Center, Amersfoort, Netherlands

    Background/Purpose: Up to 87% of patients with anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) have ear, nose and throat (ENT) involvement, which can lead to…
  • Abstract Number: 0729 • ACR Convergence 2021

    A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects

    Ismail Simsek1, Christopher Swearingen1, Heli Ghandehari1, Sarah Kennedy2, Jeyanesh Tambiah1, Yusuf Yazici3 and Nebojsa Skrepnik4, 1Biosplice Therapeutics, Inc., San Diego, CA, 2Biosplice Therapeutics, Inc, San Diego, CA, 3New York University School of Medicine, La Jolla, CA, 4Tucson Orthopaedic Institute, Tucson

    Background/Purpose: Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, is in development as a knee osteoarthritis (OA) treatment. To…
  • Abstract Number: 0730 • ACR Convergence 2021

    Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study

    Amy Halseth1, Nancy Lane2, Sarah Kennedy3, Christopher Swearingen1, Victor Lopez1, Ismail Simsek1, Mark Fineman1 and Yusuf Yazici4, 1Biosplice Therapeutics, Inc., San Diego, CA, 2University of California Davis, Hillsborough, CA, 3Biosplice Therapeutics, Inc, San Diego, CA, 4New York University School of Medicine, La Jolla, CA

    Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…
  • Abstract Number: 0778 • ACR Convergence 2021

    Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis

    Kathryn Torok1, Franziska Rosser2, Kirsten Rose-Felker1, Vibha Sood1, Geoffrey Kurland1, Adam Olson1, Meghan Frost1, Vickie Vandergrift1, Shawna McIntyre1, Alisha Maslanka3, Kaila Schollaert-Fitch1, Jessie Barnum1 and Paul Szabolcs1, 1University of Pittsburgh, Pittsburgh, PA, 2UPMC Children's Hospital of Pittbsurgh, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a rare autoimmune disease associated with life-threatening multi-organ inflammation and fibrosis. As in adults, jSSc organ involvement includes vascular,…
  • Abstract Number: 0781 • ACR Convergence 2021

    Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)

    Suzanne Li1, Aaron Thammavongxay2, Maria Ibarra3, Kathryn Torok4, Polly Ferguson5, C Egla Rabinovich6, Robert Fuhlbrigge7, Katie Stewart8, Elena Pope9, Ronald Laxer10, Sandy Hong11, Thomas Mason12, Mara Becker13, Gloria Higgins14, Fatma Dedeoglu15 and for the CARRA Legacy Registry16, 1Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, 2Bergen Academies, Hackensack, NJ, 3Children's Mercy Hospital, Kansas City, MO, 4University of Pittsburgh, Pittsburgh, PA, 5University of Iowa Carver College of Medicine, Iowa City, IA, 6Duke Childrens Hospital & Health Center, Durham, NC, 7University of Colorado, Denver, CO, 8UT Southwestern, Dallas, TX, 9Hospital for Sick Kids, Toronto, ON, Canada, 10SickKids, Toronto, ON, Canada, 11University of Iowa Stead Family Children's Hospital, Iowa City, IA, 12Mayo Clinic, Rochester, MN, 13Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, 14Ohio State University, Columbus, OH, 15Boston Children's Hospital, Boston, MA, 16Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI

    Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
  • Abstract Number: 1124 • ACR Convergence 2021

    Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach

    Lucy Abraham1, Robert Dworkin2, Dennis C. Turk3, John D. Markman2, David A. Williams4, Andrew G Bushmakin5, Jerry A. Hall6, David C. Semel7, Joseph C Cappelleri5 and Ruoyong Yang8, 1Pfizer Ltd., Tadworth, United Kingdom, 2University of Rochester, Rochester, NY, 3University of Washington, Seattle, WA, 4University of Michigan, Ann Arbor, MI, 5Pfizer Inc, Groton, CT, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer, New York, NY, 8Pfizer Inc., New York, NY

    Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
  • Abstract Number: 1256 • ACR Convergence 2021

    Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

    Roya Hosseini1, Souhiela fawaz2 and Enrique Seoane-Vazquez2, 1Chapman University School of Pharmacy, Aliso Viejo, CA, 2Chapman University School of Pharmacy, Irvine, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by polyarthritis of small and large joints. RA is the second most common type…
  • Abstract Number: 1529 • ACR Convergence 2021

    Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy

    Huifeng Yun1, Brian LaMoreaux2, Lang Chen3, Stephanie Ledbetter3, Megan Francis-Sedlak2, Kenneth Saag3, Ted Mikuls4 and Jeffrey Curtis5, 1University of Alabama Birmingham, Birmingham, AL, 2Horizon Therapeutics plc, Deerfield, IL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Nebraska Medical Center, Omaha, NE, 5Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
  • Abstract Number: 1764 • ACR Convergence 2021

    Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients

    Kelley Brady, Roberta Alexander, Rory Bloch, Mark Rudolph, Karina Baggiani, Deborah Stimson and Anja Kammensheidt, Exagen Inc., Vista, CA

    Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…
  • Abstract Number: 1815 • ACR Convergence 2021

    Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis

    yan li1, Kunpeng Li1, Zheng Zhao1, yanyan wang1, Jingyu Jin1, jianglin zhang1, Jian Zhu1 and feng huang2, 1First Medical Center, General Hospital of Chinese People's Liberation Army, Beijing, China (People's Republic), 2Chinese PLA General Hospital, Beijing, China (People's Republic)

    Background/Purpose: Iguratimod, also known as T-614, is a new type of small molecule compound with anti-inflammatory and immunomodulatory effects; It was listed in China(2011) and…
  • Abstract Number: 1829 • ACR Convergence 2021

    Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options

    Rita Torres1, Santiago Manica2 and Fernando Santos2, 1Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, 2Hospital Egas Moniz, Lisboa, Portugal

    Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…
  • Abstract Number: 098 • 2020 Pediatric Rheumatology Symposium

    Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

    Manuela Pardeo1, Claudia Bracaglia 1, Emanuela Sacco 1, Denise Pires Marafon 1, Antonella Insalaco 1, Giulia Marucci 1, Rebecca Nicolai 2, Virginia Messia 1 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) should be considered as a polygenic autoinflammatory disease. Interleukin 1 (IL-1) has been shown to be a major mediator…
  • Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium

    Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers

    Julia Harris1, Esi Morgan 2, Janalee Taylor 2, Tingting Qiu 3, Nancy Griffin 3, Anne Paul 4, C. April Bingham 5, Danielle Bullock 6, Kerry Ferraro 7, Mileka Gilbert 8, Y. Ingrid Goh 9, Olha Halyabar 10, Karla Jones 11, Melanie Kohlheim 12, Daniel J. Lovell 13, Emily Smitherman 14, Anjie Vago 7, Jennifer Weiss 15, Cagri Yildirim-Toruner 11, Angela Young 7, Michelle Batthish 16, Beth Gottlieb 17, Melissa Hazen 18, Ronald Laxer 19, Tzielan Lee 20, Melissa Mannion 14, Judyann Olson 21, Michael Shishov 22, Salma Siddique 23, Charles Spencer 24, Mary Toth 25, Sheetal Vora 26 and Jon Burnham 27, 1Children's Mercy Kansas City, Overland Park, 2Cincinnati Children's Hospital, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, 4Cincinnati Children's Hospital Medical Centre, Cincinnati, 5Penn State Children's Hospital, Allentown, 6University of Minnesota, Minneapolis, 7Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 8Medical University of South Carolina, Charleston, South Carolina, 9The Hospital for Sick Children, Toronto, Canada, 10Children's Hospital/Boston Medical Center, Boston, 11Nationwide Children's Hospital, Columbus, 12, 13Cincinnati, 14University of Alabama at Birmingham, Birmingham, 15Hackensack University Medical Center, Hackensack, 16McMaster University, Hamilton, Canada, 17Cohen Children's Medical Center, Lake Success, 18Boston, 19The Hospital for Sick Children and University of Toronto, Toronto, Canada, 20Stanford Children's, Palo Alto, 21Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, 22Phoenix Children's Hospital, Phoenix, 23Nemours/A.I.duPont Hospital for Children, Wilmington, 24Jackson, 25Nemours Foundation, Orlando, 26Atrium Health Levine Children's Hospital, Charlotte, 27Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
  • 1
  • 2
  • 3
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology